« Back to Record
Citation APA

Dreyling, M., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Peña, C., Neves, M., Childs, B. B., Morschhauser, F., Zinzani, P. P., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. S., Verhoef, G. E. G., Linton, K., & Thieblemont, C. (2017). Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Annals of oncology, 28(9), 2169-2178. doi:10.1093/annonc/mdx289


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/260125

Dreyling, M., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Peña, C., Neves, M., Childs, B. B., Morschhauser, F., Zinzani, P. P., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. S., Verhoef, G. E. G., Linton, K., & Thieblemont, C. (2017). Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Annals of oncology, 28(9), 2169-2178. doi:10.1093/annonc/mdx289